Naborforce vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 41)
Naborforce logo

Naborforce

EmergingHealthcare

General

Richmond VA YC W20 on-demand senior companion platform with 1,000%+ pandemic revenue growth; $13.5M total ($9M Translink Series A 2022) connecting older adults with vetted Nabors for companionship, errands, and transportation competing with Papa.

AI VisibilityBeta
Overall Score
C41
Category Rank
#350 of 596
AI Consensus
75%
Trend
stable
Per Platform
ChatGPT
42
Perplexity
45
Gemini
44

About

Naborforce is a Richmond, Virginia-based on-demand senior companionship and assistance platform — backed by Y Combinator (W20) with approximately $13.5 million in total funding including a $9 million Series A in August 2022 led by Translink Capital with Claritas Capital, The Artemis Fund, and TechStars — providing older adults with on-demand access to a vetted network of 'Nabors' (friendly helpers who are not healthcare providers) for social engagement, companionship, errands, transportation, and light assistance around the home. Founded in 2016, Naborforce grew revenue over 1,000% and expanded its client base over 800% during the COVID-19 pandemic, demonstrating the pent-up demand for senior social connection and practical assistance services.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

41
Overall Score
90
#350
Category Rank
#2
75
AI Consensus
83
stable
Trend
stable
42
ChatGPT
92
45
Perplexity
93
44
Gemini
89
39
Claude
96
35
Grok
95

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.